CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 3,532 target
Drug / intervention
Enoxaparin sodiumdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00077844
NCT00077844Phase 3Completed
CompareCT.gov

An International Phase 2-3, Stratified, Randomized, Open-label, Parallel-group Clinical Trial to Evaluate the Safety and Efficacy of a Single Intravenous Bolus of Enoxaparin Versus Intravenous Unfractionated Heparin in Patients Undergoing Non-emergent Percutaneous Coronary Intervention

Sanofi·interventional·Posted Feb 18, 2004·Updated Jan 11, 2011

In Brief

A Phase 3 clinical trial evaluating Enoxaparin sodium for Percutaneous Coronary Intervention. Completed, enrolled 3,532 participants.

Detailed Summary

The purpose of this study is to evaluate the efficacy and safety of intravenous enoxaparin versus intravenous unfractionated heparin (UFH) in patients undergoing non-emergent PCI, as assessed by measuring the incidence of non-coronary artery bypass graft (CABG) major and minor bleeding.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPercutaneous Coronary Intervention
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 18, 2004
Enrollment StartJan 1, 2004
Primary CompletionSep 1, 2005
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 22.4 years ago

Interventions

Enoxaparin sodiumdrug